|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.18 USD | +8.53% |
|
+11.84% | +14.31% |
| 02-06 | Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating | MT |
| 02-06 | Biogen Inc., Q4 2025 Earnings Call, Feb 06, 2026 |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 10.51B | 9.69B | 9.84B | 9.68B | 9.89B | |||||
Other Revenues, Total | 476M | 485M | - | - | - | |||||
Total Revenues | 10.98B | 10.17B | 9.84B | 9.68B | 9.89B | |||||
Cost of Goods Sold, Total | 2.11B | 2.28B | 2.53B | 2.31B | 2.08B | |||||
Gross Profit | 8.87B | 7.9B | 7.3B | 7.37B | 7.81B | |||||
Selling General & Admin Expenses, Total | 2.68B | 2.41B | 2.5B | 2.39B | 2.43B | |||||
R&D Expenses | 2.5B | 2.23B | 2.46B | 2.02B | 1.75B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 252M | 246M | 241M | 386M | 507M | |||||
Other Operating Expenses | 7.2M | -7.4M | 219M | 254M | 290M | |||||
Other Operating Expenses, Total | 5.44B | 4.88B | 5.42B | 5.04B | 4.98B | |||||
Operating Income | 3.44B | 3.01B | 1.88B | 2.32B | 2.82B | |||||
Interest Expense, Total | -254M | -247M | -247M | -250M | -268M | |||||
Interest And Investment Income | 11M | 89.3M | 276M | 67.6M | 125M | |||||
Net Interest Expenses | -243M | -157M | 29.6M | -183M | -142M | |||||
Income (Loss) On Equity Invest. | 34.9M | 2.6M | - | - | - | |||||
Currency Exchange Gains (Loss) | -22.4M | -35.5M | -50.4M | -30.9M | -28.6M | |||||
Other Non Operating Income (Expenses) | -4M | -3M | -1.7M | -26.5M | -110M | |||||
EBT, Excl. Unusual Items | 3.2B | 2.82B | 1.86B | 2.08B | 2.54B | |||||
Restructuring Charges | - | -131M | -243M | -73.9M | -78.4M | |||||
Merger & Related Restructuring Charges | - | - | -28.4M | -2.8M | -217M | |||||
Gain (Loss) On Sale Of Investments | -825M | 1.23B | -291M | -100M | -19.7M | |||||
Gain (Loss) On Sale Of Assets | - | 504M | - | 88.6M | - | |||||
Asset Writedown | -629M | -120M | - | -60.2M | -60.8M | |||||
In Process R&D Expenses | -18M | - | - | - | -472M | |||||
Legal Settlements | - | -917M | - | - | -105M | |||||
Other Unusual Items | 50.7M | 209M | - | -27.7M | -33.6M | |||||
EBT, Incl. Unusual Items | 1.78B | 3.59B | 1.3B | 1.91B | 1.56B | |||||
Income Tax Expense | 52.5M | 633M | 135M | 274M | 264M | |||||
Earnings From Continuing Operations | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B | |||||
Net Income to Company | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B | |||||
Minority Interest | -172M | 85.3M | -400K | - | - | |||||
Net Income - (IS) | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B | |||||
Net Income to Common Incl Extra Items | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B | |||||
Net Income to Common Excl. Extra Items | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 10.44 | 20.97 | 8.02 | 11.21 | 8.83 | |||||
Basic EPS - Continuing Operations | 10.44 | 20.97 | 8.02 | 11.21 | 8.83 | |||||
Basic Weighted Average Shares Outstanding | 149M | 145M | 145M | 146M | 146M | |||||
Net EPS - Diluted | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | |||||
Diluted EPS - Continuing Operations | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | |||||
Diluted Weighted Average Shares Outstanding | 150M | 146M | 146M | 146M | 147M | |||||
Normalized Basic EPS | 12.27 | 12.72 | 8.03 | 8.94 | 10.85 | |||||
Normalized Diluted EPS | 12.23 | 12.66 | 7.98 | 8.92 | 10.8 | |||||
American Depositary Receipts Ratio (ADR) | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | |||||
Supplemental Items | ||||||||||
EBITDA | 3.92B | 3.53B | 2.38B | 3B | 3.6B | |||||
EBITA | 3.69B | 3.26B | 2.12B | 2.71B | 3.33B | |||||
EBIT | 3.44B | 3.01B | 1.88B | 2.32B | 2.82B | |||||
EBITDAR | 4.02B | 3.63B | 2.52B | 3.12B | 3.73B | |||||
Total Revenues (As Reported) | 10.98B | 10.17B | 9.84B | 9.68B | 9.89B | |||||
Effective Tax Rate - (Ratio) | 2.95 | 17.61 | 10.43 | 14.37 | 16.94 | |||||
Current Domestic Taxes | 342M | 734M | 393M | 499M | 57.4M | |||||
Current Foreign Taxes | 137M | 67.9M | 48.4M | -67.5M | -155M | |||||
Total Current Taxes | 479M | 801M | 441M | 432M | -98M | |||||
Deferred Domestic Taxes | -254M | -326M | -600M | -172M | 321M | |||||
Deferred Foreign Taxes | -172M | 157M | 294M | 13.7M | 40.6M | |||||
Total Deferred Taxes | -427M | -169M | -306M | -158M | 362M | |||||
Normalized Net Income | 1.83B | 1.85B | 1.16B | 1.3B | 1.59B | |||||
Interest Capitalized | 36.3M | 17.1M | 21.7M | 3.2M | 3.4M | |||||
Non-Cash Pension Expense | 29.1M | 25.9M | 21.2M | 21.3M | 20.7M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 98.7M | 54.1M | 71.4M | 66.8M | 71.9M | |||||
Selling and Marketing Expenses | 98.7M | 54.1M | 71.4M | 66.8M | 71.9M | |||||
Research And Development Expense From Footnotes | 3.4B | 2.6B | 2.7B | 2.49B | 2.29B | |||||
Net Rental Expense, Total | 97.9M | 95.6M | 140M | 125M | 123M | |||||
Imputed Operating Lease Interest Expense | 29.1M | 28M | 42.64M | 35.93M | 39.73M | |||||
Imputed Operating Lease Depreciation | 68.8M | 67.6M | 97.66M | 89.37M | 82.87M | |||||
Stock-Based Comp., Other (Total) | 251M | 264M | 658M | 342M | 291M | |||||
Total Stock-Based Compensation | 251M | 264M | 658M | 342M | 291M |
- Stock Market
- Equities
- BIIB Stock
- Financials Biogen Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















